Secreted EMC10 inhibits muscle GLUT4 activity and glucose uptake in mice

Shuoshuo Jin, Wei Wu, Shan Liu, Yahao Wang, Qi Huang, Kunlun He, Yunzhi Ni, Kuangyang Chen, Jinya Huang, Lijie Liu, Jiarong Dai, Chongwen Zhan, Xinru Wang, Yihui Guan, Matthias Blüher, Xuanchun WangJournal of Biological Chemistry 2025 · DOI

TL;DR

This study reveals that a secreted protein, scEMC10, acts as a key inhibitor of glucose uptake in skeletal muscle by suppressing the expression and membrane translocation of the GLUT4 transporter. This discovery suggests that targeting scEMC10 could be a promising therapeutic strategy for managing type 2 diabetes.

What Problem Does This Paper Address?

Maintaining stable blood glucose levels is crucial for overall health, and skeletal muscle plays a starring role in this process, accounting for about 80% of postprandial glucose disposal. In type 2 diabetes, this vital function is significantly impaired, contributing to hyperglycemia. Glucose uptake into muscle cells is a complex process involving delivery, uptake, and intracellular metabolism, primarily mediated by the GLUT4 transporter. While insulin and exercise are known to stimulate glucose uptake, the precise molecular mechanisms that can inhibit this process, and how these might be dysregulated in diabetes, are not fully understood. This paper investigates the role of a specific secreted protein, scEMC10, which has previously been linked to impaired glucose tolerance and insulin resistance, in modulating muscle glucose uptake.

Methods

The researchers employed a multi-pronged approach using both cell culture and animal models:

  • Cell Culture: They used L6-GLUT4myc myoblasts and C2C12 myoblasts to study the effects of recombinant scEMC10 protein on glucose uptake and GLUT4 behavior. Techniques included:
  • 2-NBDG Uptake Assay: A fluorescent glucose analog (2-NBDG) was used to directly measure glucose uptake into myotubes via flow cytometry.
  • Immunofluorescence Staining: This technique visualized the location of GLUT4 within the cells, specifically assessing its translocation to the plasma membrane, using antibodies against GLUT4 and F-actin.
  • Quantitative PCR (qPCR): Used to measure mRNA levels of GLUT4 and various transcriptional factors involved in its regulation.
  • Western Blotting: Employed to quantify protein levels of GLUT4, as well as key signaling molecules like phosphorylated AMPK, AKT, and their downstream targets.
  • Animal Models:
    • PET-CT Imaging: Used with the radiotracer 18F-FDG to non-invasively assess glucose uptake in the gastrocnemius muscle of mice.
  • Genetically Modified Mice: Emc10 gene knockout (KO) mice were compared to wild-type (WT) littermates to understand the role of endogenous scEMC10.
  • Recombinant Protein Injection: Mice were injected with recombinant scEMC10 protein to mimic elevated levels of the secreted factor.
  • Antibody Neutralization: Mice were treated with a neutralizing antibody against scEMC10 to investigate the effects of blocking its activity.
  • Tissue Analysis: Gastrocnemius muscle tissue was collected for qPCR and Western blot analysis to assess GLUT4 expression and signaling pathways.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • scEMC10 as a direct inhibitor of GLUT4: The study provides strong evidence that scEMC10 directly interferes with GLUT4's ability to get to the cell surface and function, both in basal conditions and when stimulated by insulin. This is a significant finding, as it pinpoints a specific molecular player in the dysregulation of glucose uptake.
  • Dual mechanism of GLUT4 suppression: scEMC10 doesn't just block GLUT4 from moving to the membrane; it also reduces the amount of GLUT4 produced by decreasing its mRNA and protein levels. This two-pronged attack makes its inhibitory effect particularly potent.
  • AMPK and Insulin signaling are key targets: The research uncovers that scEMC10 dampens crucial signaling pathways—AMPK (important for exercise-induced uptake) and insulin signaling (via Akt)—that are essential for regulating GLUT4. This explains how scEMC10 exerts its effects at a molecular level.
  • Therapeutic potential of scEMC10 inhibition: The most exciting takeaway is that blocking scEMC10 with a neutralizing antibody not only reverses its inhibitory effects in mice but also improves glucose uptake and tolerance. This strongly suggests that targeting scEMC10 could be a viable strategy for treating type 2 diabetes.

Key Results

  • Recombinant scEMC10 treatment significantly reduced glucose uptake in L6-GLUT4myc myotubes, both under basal conditions and when stimulated by insulin.
  • scEMC10 treatment led to decreased GLUT4 mRNA and protein levels in C2C12 myotubes in a time- and dose-dependent manner.
  • Immunofluorescence studies showed that scEMC10 prevented insulin-induced translocation of GLUT4 to the plasma membrane in myoblasts.
  • In mice, Emc10 KO mice exhibited increased glucose uptake in skeletal muscle compared to WT mice, particularly under a high-fat diet. Conversely, injecting recombinant scEMC10 reduced glucose uptake.
  • scEMC10 significantly suppressed the phosphorylation of AMPK and its downstream targets (TBC1D1, ACC) in both myotubes and mouse skeletal muscle.
  • scEMC10 also inhibited insulin-induced Akt phosphorylation in C2C12 myotubes.
  • Treatment with a scEMC10-neutralizing antibody in mice led to increased GLUT4 expression and membrane translocation in skeletal muscle, improving glucose uptake.
  • scEMC10 downregulated the expression of key genes involved in intracellular glucose metabolism, such as hexokinase II and phosphofructokinase 2.

Limitations and Future Work

The authors acknowledge several limitations:

  • Small sample size in PET-CT studies: The animal studies using PET-CT had small sample sizes, which prevented achieving statistical significance in some analyses. This warrants larger studies to confirm these findings.
  • Use of cell line models: While L6-GLUT4myc cells were used as a substitute for primary muscle cells due to technical challenges, the authors note a disconnect between cell line findings and primary muscle tissue. Further studies with more direct models are needed.
  • Elusive molecular mechanism for AMPK/insulin signaling modulation: While scEMC10's impact on AMPK and insulin signaling is demonstrated, the precise molecular mechanisms by which scEMC10 influences these pathways remain to be fully elucidated. The authors suggest exploring scEMC10's role in cytosolic Ca2+ regulation as a potential avenue for future research.

Future work should focus on validating these findings in larger animal cohorts, exploring the detailed molecular mechanisms of scEMC10's interaction with signaling pathways, and ultimately translating these discoveries into therapeutic interventions for type 2 diabetes.

Summary updated

Abstract

Manipulation of glucose uptake plays a critical role in muscle glucose disposal. We have shown that the secreted isoform of endoplasmic reticulum membrane protein complex subunit 10 (scEMC10) impairs glucose tolerance in mice, and serum scEMC10 is positively associated with insulin resistance and hyperglycemia in humans. In this study, we attempt to investigate whether modulation of muscle glucose uptake implicates in the scEMC10-impacted glucose homeostasis. In mouse models, Emc10 gene KO elevated, whereas recombinant scEMC10 treatment reduced muscle glucose uptake and GLUT4 expression. In myoblasts, scEMC10 inhibited both GLUT4 expression and membrane translocation and downregulated expression of genes associated with intracellular glucose metabolism. Mechanistically, scEMC10 suppressed the activation of muscle AMP-activated protein kinase and insulin signaling cascades. Inhibition of scEMC10 via a neutralizing antibody enhanced muscle glucose uptake in mice, in parallel with heightened GLUT4 expression and membrane translocation, which accounts for an improved whole-body glucose homeostasis. In conclusion, this work identifies scEMC10 as a novel suppressor of muscle glucose uptake and suggests inhibition of scEMC10 as a therapeutic strategy for type 2 diabetes.
BibTeX
@article{jin2025secreted,
  author = {Shuoshuo Jin and Wei Wu and Shan Liu and Yahao Wang and Qi Huang and Kunlun He and Yunzhi Ni and Kuangyang Chen and Jinya Huang and Lijie Liu and Jiarong Dai and Chongwen Zhan and Xinru Wang and Yihui Guan and Matthias Blüher and Xuanchun Wang},
  title = {{Secreted EMC10 inhibits muscle GLUT4 activity and glucose uptake in mice}},
  journal = {Journal of Biological Chemistry},
  year = {2025},
  doi = {10.1016/j.jbc.2025.110296},
}
Figure